Summary
Introduction
Streptococcus agalactiae , also named group B Streptococcus (GBS), is the major cause of bacterial sepsis and meningitis in neonates and has emerged as an increasingly common cause of invasive disease in immunocompromised people (Farley et al ., 1993; Baker and Edwards, 1995) . The interaction of GBS with its host is a complex process involving the colonization and penetration of epithelial and endothelial surfaces and the evasion of the immune defence (Spellerberg, 2000) . In streptococci, fibrinogen binding has been shown to play a significant role in adhesion to host surfaces (Courtney et al ., 1994) and protection from the immune system (Courtney et al ., 1997; Thern et al ., 1998; Ringdahl et al ., 2000) . Therefore, several studies have addressed the molecular basis of fibrinogen binding in streptococci from serological groups A, C and G (Fischetti, 1989; Meehan et al ., 1998; Vasi et al ., 2000) .
Fibrinogen is a 330 kDa glycoprotein found in high concentrations in blood plasma (Fuss et al ., 2001; Mosesson et al ., 2001) . It is a hexamer composed of each of two A a -, B b -and g -chains linked together by disulphide bonds. Fibrinogen is a key player in haemostasis and mediates platelet adherence and aggregation at sites of injury. Furthermore, it is cleaved by thrombin to form fibrin, which is the major component of blood clots. Fibrinogen also plays a role in opsonophagocytosis. It has been shown to inhibit the binding of the activated complement factor C3b, thereby blocking the activation of the alternative complement pathway (Whitnack et al ., 1984; Whitnack and Beachey, 1985) . The newborn's unique susceptibility to disseminated GBS infections has been associated with a relative complement deficiency (Mills et al ., 1979; Edwards et al ., 1983) . Fibrinogen binding of GBS may thus play an important role in the inhibition of the residual complement activity in the newborn (Noel et al ., 1991) .
The interaction of GBS with human fibrinogen has been demonstrated in several studies (Schönbeck et al ., 1981; Lämmler et al ., 1983; Chhatwal et al ., 1985; Spellerberg et al. , 2002) . However, the molecular basis of fibrinogen binding in GBS remained unknown.
In the present study, we describe the isolation and characterization of a fibrinogen receptor from GBS. We also present data about the distribution and composition of the respective genes in different clinical isolates of GBS. Furthermore, we tested the importance of this receptor for fibrinogen binding of GBS and for resistance of the bacteria against opsonophagocytosis. In binding assays, the fibrinogen binding site was localized and subjected to a detailed biochemical analysis. From these results, we were able to predict a small consensus motif for fibrinogen binding.
Results

The fibrinogen receptor of GBS has a proteinaceous nature
The molecular basis of fibrinogen binding in GBS was studied using GBS strain 6313, a clinical isolate belonging to serotype III. In binding experiments with radiolabelled fibrinogen, strain 6313 accumulated about 50% of the total fibrinogen on its surface. Treatment of the bacteria with either trypsin or pronase reduced the amount of bound fibrinogen to levels below 5%, indicating a proteinaceous nature of the fibrinogen-binding structures of GBS 6313. In competitive inhibition experiments, binding of human fibrinogen to GBS 6313 was shown to be saturable (Fig. 1A) , revealing a specific interaction between GBS and fibrinogen. Plotting of the obtained data according to Scatchard resulted in a linear plot (Fig. 1B) , indicating a homogeneous population of fibrinogen binding sites on the surface of GBS 6313. The dissociation constant of bound fibrinogen was calculated to be 2 ¥ 10 -8 M.
The fibrinogen receptor from GBS 6313 is a highly repetitive protein
An Escherichia coli cosmid gene library of GBS 6313 was screened by colony blotting for the presence of fibrinogenbinding E. coli clones, resulting in the identification of three clones that revealed strong interaction with human fibrinogen. Partial digestion of one of the cosmids with Sau 3A and subcloning of fragments in the range 2-3 kb in plasmid pTEX5236 resulted in the isolation of plasmid pTEXfbsA, carrying a 2.6 kb insert that conferred fibrinogen binding to E. coli DH5 a . The insert of pTEXfbsA was sequenced, and the analysis of the obtained sequence identified one open reading frame (ORF) of 1329 bp, designated fbsA as it encodes a fibrinogen-binding protein from S. agalactiae ( Fig. 2A) . The fbsA gene is preceded by a typical ribosomal binding site (AGGAGA) and followed by a sequence resembling a transcriptional terminator ( D G° = -18 kcal mol -1 ). Analysis of the fbsAencoding region revealed for the deduced FbsA protein typical features of a surface-located protein from streptococci ( Fig. 2B) , i.e. a signal peptide sequence of 35 amino acids (Nielsen et al ., 1997) at its N-terminus and a cell wall-spanning region (CWR) and anchor motif (LPKTG) (Schneewind et al ., 1993) at its C-terminus, followed by a membrane-spanning region (MSR) and a charged tail. The fbsA gene encodes a primary translation product of 442 amino acids ( M r 51 319), which is putatively processed post-translationally to yield a mature protein of 378 amino acids ( M r 44 260). Secondary structure prediction according to the method of Garnier et al . (1996) revealed that 72% of the mature FbsA consists of ahelices, primarily located in the N-terminal region of FbsA. The most striking feature of FbsA is its highly repetitive nature: FbsA carries 19 complete repeats of 16 amino acids that are almost identical. Fourteen of the 19 repeats are composed of the sequence motif 'GNVLERRQRD AENRSQ', whereas two repeats (3 and 10) carry an R14K substitution, and three repeats (2, 9 and 19) possess both an A11V and an R14K substitution. Computer-assisted comparison of FbsA with proteins deposited in public databases revealed no similarity to known proteins or polypeptides.
To analyse the transcriptional organization of fbsA in GBS 6313, total RNA from this strain was hybridized with an fbsA -specific probe, resulting in the detection of a 1.45 kb transcript (data not shown). As the fbsA gene from strain 6313 has a size of 1329 bp, this result indicates a monocistronic organization of fbsA in GBS strain 6313.
FbsA proteins from different GBS strains vary in the number and composition of the single repeats
Among the nine different serotypes from GBS, serotypes Ia, Ib, II, III and V comprise the majority of clinical isolates (Spellerberg, 2000) . Southern blot experiments with clinical GBS isolates belonging to these serotypes were performed to analyse the presence of fbsA in medically relevant strains from GBS. Four strains from serotype IV, which had been isolated from cows with mastitis, were also included in this study. By Southern blot analysis, the fbsA gene was detected in 25 out of 27 strains (Fig. 3) , indicating a wide distribution of fbsA in different serotypes of GBS. In some of the samples, in addition to a major fbsA -specific band, an additional faint band was observed. By polymerase chain reaction (PCR) analysis of chromosomal DNA from these strains with fbsA -specific primers, one single DNA fragment was amplified in each of these strains (data not shown), indicating that the additional faint bands resulted from a partial digest of the chromosomal DNA. Interestingly, in Southern blot as well as in PCR analysis, the size of the fbsA gene varied significantly between the individual strains. To unravel the molecular basis of this size variation, the fbsA gene was amplified by PCR from the GBS strains 706 S2 (serotype Ia), O176 H4A (serotype II), SS1169 (serotype V) and O90R (a capsule mutant derived from a serotype Ia strain) and sequenced. Analysis of the obtained sequences revealed one ORF in each PCR product with high identity to fbsA from GBS strain 6313. Comparison of the fbsA -deduced polypeptides showed that the N-terminal 44 amino acids of the different FbsA proteins are identical except for a P32S substitution in strain 706 S2. Also, in the C-terminal 94 amino acids of FbsA, the identity between the different proteins ranges from 94% to 100%. The different FbsA proteins are also functionally similar in these regions, i.e. all the deduced FbsA proteins possess a putative signal peptide at their N-termini and a putative cell wall anchor at their C-termini (Fig. 2B) . As expected from the Southern blot experiments, the size of the single proteins is significantly different. The primary translation product of fbsA is 410 amino acids for strain 706 S2, 186 amino acids for strain 176 H4A, 298 amino acids for strain O90R and 618 amino acids for strain SS1169. As shown in Fig. 2B , the different sizes between the single FbsA proteins result exclusively from a different number of repeats within the individual proteins. Figure 2B also shows that the individual repeats of the deduced FbsA proteins reveal differences in their amino acid composition. Surprisingly, all repeats in FbsA, except for the last one in strain SS1169, show an E12D substitution that is not present in the repeats of the other FbsA proteins. Analysis of the repeatencoding region of the different fbsA genes at the DNA level revealed 93-98% identity among the repeats of the GBS strains 6313, 706 S2, 176 H4A and O90R, whereas strain SS1169 exhibited only 81% identity between its single repeats. Thus, the fbsA gene from different GBS strains appears to be highly variable in the number of and flexible in the composition of single repeat-encoding units.
FbsA is the major fibrinogen-binding protein in GBS 6313 and plays a role in resistance of GBS against opsonophagocytosis
To analyse the contribution of FbsA to the fibrinogen binding of strain 6313, we constructed an fbsA deletion mutant of this strain. Southern blot analysis revealed the successful deletion of fbsA in the mutant (data not shown), which was accordingly termed 6313 D fbsA . Mutant and parental strains were tested for their binding of soluble and immobilized fibrinogen. Although strain 6313 exhibited about 50% binding of 125 I-labelled soluble fibrinogen, mutant 6313 D fbsA bound < 2% (data not shown). Similarly, in binding experiments using fluorescein isothiocyanate (FITC)-labelled bacteria, about 45% of the total bacteria from strain 6313 but < 2% of mutant 6313 D fbsA bound to immobilized fibrinogen (data not shown). From these results, it can be concluded that FbsA is the major fibrinogen-binding protein from GBS 6313, and that it mediates the binding of the bacteria to both soluble and immobilized fibrinogen.
To analyse the importance of FbsA for protecting GBS from opsonophagocytosis, the GBS strains 6313 and 6313 D fbsA were tested for survival in a classical bactericidal assay in whole human blood. After inoculation of heparinized human blood with 100 ± 30 colony-forming units (cfu) of either of the two strains, both strains revealed growth; however, after 3 h of incubation, strain 6313 grew to 2500 ± 500 cfu per assay, whereas strain 6313 D fbsA grew to only 800 ± 100 cfu per assay. As an altered growth rate of mutant 6313 D fbsA would have a significant effect on the outcome of the bactericidal assay, the growth curves of strains 6313 and 6313 D fbsA in THY medium and in heat-inactivated human serum were compared by measuring the change in optical density of the cultures over time. Under both culture conditions, the two strains revealed identical doubling times (data not shown), suggesting identical growth rates of the two strains in the absence of complement. This finding indicates that the different cell numbers of the GBS strains 6313 and 6313 DfbsA after incubation in human blood are caused by a reduced resistance of GBS 6313DfbsA against opsonophagocytosis, suggesting a role for FbsA in preventing opsonization.
The fibrinogen-binding region is located in the repeat region of FbsA
For functional analysis of FbsA, a truncated FbsA polypeptide , devoid of a signal peptide and a membrane-spanning region, was synthesized as a hexahistidyl fusion protein in Escherichia coli BL21 and purified by affinity chromatography. In Western blot experiments, FbsA-19 revealed binding to human fibrinogen (Fig. 4) , confirming FbsA as a fibrinogen receptor from GBS. To localize the fibrinogen-binding region in the FbsA protein, the N-terminal and C-terminal regions of FbsA were synthesized as FbsA-N and FbsA-C fusion proteins and tested for fibrinogen binding. As shown in Fig. 4 , fibrinogen binding was observed for FbsA-N but not for FbsA-C, indicating that the N-terminal repeats of FbsA mediate fibrinogen binding.
Fibrinogen binding is dependent on the number of repeats in FbsA
In competitive inhibition experiments with 125 I-labelled fibrinogen, different proteins were tested for their ability to interfere with the binding of radiolabelled fibrinogen to GBS. As a control, the non-fibrinogen-binding surface protein Bsp from GBS (Reinscheid et al., 2002) was tested for inhibition of binding of fibrinogen to GBS. As shown in Fig. 5 , the addition of increasing concentrations of Bsp had no effect on fibrinogen binding by GBS. However, increasing concentrations of purified FbsA-19 substantially inhibited the binding of 125 I-labelled fibrinogen to GBS 6313 cells. To analyse whether the number of repeats of FbsA has an effect on fibrinogen binding, a derivative of FbsA with only nine repeats (FbsA-9) was tested for its ability to inhibit fibrinogen binding by GBS. Interestingly, a significantly higher concentration of FbsA-9 had to be used to obtain a comparable inhibition of fibrinogen binding to that obtained with FbsA-19. This finding indicates that increasing numbers of repeats of FbsA increase either the affinity for fibrinogen and/or the amount of fibrinogen that is bound by FbsA.
Mapping of the binding domain within FbsA
To characterize further the interaction of FbsA and fibrinogen at the molecular level, FbsA-derived synthetic peptides were tested for their interaction with human fibrinogen. First, we analysed a single repeat unit of FbsA (GNVLERRQRDAENRSQ) for its ability to interact with human fibrinogen. In dot blot experiments, a strong interaction of this synthetic peptide with human fibrinogen was observed, whereas a randomized peptide containing identical amounts of amino acids but in a different order showed no binding of fibrinogen (Fig. 6 ). This result shows that a single repeat unit of FbsA is capable of specific binding to human fibrinogen. To identify amino acids in the repeat region that are essential for fibrinogen binding, we synthesized peptides that contained single alanine replacements at different positions. Testing of these peptides for their interaction with fibrinogen ( Fig. 6) A comprehensive analysis of fibrinogen binding by the 16-amino-acid sequence motif was performed to identify putative conservative substitutions within the repeat regions. Therefore, synthetic peptides derived from the sequence motif 'GNVLERRQRDAENRSQ' were synthesized and spotted directly onto a membrane. Every peptide differed from each other by a single amino acid substitution. In this way, every amino acid within the repeat was successively replaced by one of the 20 proteinaceous amino acids. Testing of the individual spots for fibrinogen binding resulted in a complex picture of the interaction between fibrinogen and the repeat unit (Fig. 7) . Replacement of G 1 by any other amino acid reduced the fibrinogen binding of the repeat, although binding was not completely abolished. N2S and N2T substitutions did not affect fibrinogen binding, although replacement of N 2 by any other amino acid significantly reduced fibrinogen binding. V 3 and L 4 could not be replaced by other amino acids without significant reduction in binding function. Fibrinogen binding was not affected by E5A, E5M and E5Q substitutions, but any other amino acid in this position resulted in a lower binding of fibrinogen. Substitutions of R 6 predominantly caused loss of fibrinogen binding, whereas peptides with R6A, R6K and R6W substitutions retained little binding activity. However, replacement of R 7 by any other amino acid resulted in loss of fibrinogen binding. Q 8 could be substituted by many amino acids without an effect on binding, whereas R 9 could only be replaced by K or W without affecting binding. D10A, D10E, D10N and D10Q substitutions had no effect on fibrinogen binding, and the same was true for A11F, A11I, A11L, A11V and A11Y changes. E 12 and N 13 could be replaced by a variety of amino acids without affecting binding. In contrast, only R14K substitutions retained fibrinogen binding of the peptide. Finally, S 15 and Q 16 could be replaced by many other amino acids without loss of binding function. Derived from the result of the spotting membrane experiment, the following fibrinogen-binding motif can be postulated:
This consensus motif could not be identified in fibrinogen-binding proteins from other organisms, indicating that it represents a novel type of fibrinogen binding site. 
Fibrinogen binding to GBS can be selectively inhibited by a repeat unit
Derived from the results of the spot membrane analysis, two different synthetic peptides were tested for their ability to inhibit fibrinogen binding of GBS. One peptide (pep_FbsA) represented the original repeat unit sequence 'GNVLERRQRDAENRSQ', whereas the other peptide (pep_R6A) carried an R6A substitution. In spot membrane analysis, the latter peptide had revealed a significantly reduced binding to fibrinogen. In competitive inhibition experiments, both peptides were tested for inhibiting the binding of radiolabelled fibrinogen to GBS (Fig. 8) . A concentration of 160 mM of pep_FbsA inhibited fibrinogen binding by 80%, whereas the same concentration of pep_R6A caused only 20% inhibition of fibrinogen binding. These findings demonstrate that the soluble form of the repeat unit of FbsA is capable of fibrinogen binding. Furthermore, the difference in the inhibition of fibrinogen binding between the two peptides confirms the results of the spot membrane analysis and shows that R 6 plays an important role in fibrinogen binding.
Discussion
The presence of fibrinogen-binding structures on the surface of GBS has been recognized for several years (Schönbeck et al., 1981; Lämmler et al., 1983; Chhatwal et al., 1985) . However, the present study is the first to describe the molecular basis of fibrinogen binding in GBS. The fibrinogen receptor FbsA from GBS does not exhibit similarity to proteins in public databases, indicating that FbsA is a novel fibrinogen-binding protein. In streptococci from the serological groups A, C and G, fibrinogen binding is generally mediated by M-proteins (Fischetti, 1989; Meehan et al., 1998; Vasi et al., 2000) . It has also been speculated that M-proteins mediate fibrinogen binding in GBS (Reutersward et al., 1985) . The designation M-and M-like protein is applied to streptococcal fibrillar surface proteins with a variety of ligand activities but with common structural features, including signal and cell wallassociated sequences, variable N-terminal regions, conserved central C or A repeats and proline-rich C-terminal domains (Scott, 1990) . Although FbsA from GBS is predicted to be a predominantly a-helical protein, there are no sequence-based indications that it would attain a dimeric coiled-coil structure, its repeat region is not similar to the C or A repeats of M-proteins and the C-terminus from FbsA is not rich in prolines. Taken together, the fibrinogen-binding protein of GBS is clearly distinct from M-proteins found in other streptococcal species. Fig. 7 . Spot membrane analysis of the fibrinogen-binding repeat unit. Synthetic peptides, in which each of the amino acids of the fibrinogenbinding repeat was replaced by each of the 20 proteinaceous amino acids, were tested for fibrinogen binding. The vertical letters, printed in bold, represent the FbsA-derived fibrinogenbinding sequence 'GNVLERRQRDAENRSQ'. The horizontal letters represent those amino acids that were introduced in the synthetic peptides instead of the original amino acid in the respective position. The inactivation of the fibrinogen-binding M-protein in group A Streptococcus (GAS) results in a complete loss of fibrinogen binding (Podbielski et al., 1996; Courtney et al., 1997; Thern et al., 1998; Kotarsky et al., 2000) . Mproteins are therefore postulated to be the major fibrinogen receptors of GAS. Deletion of fbsA in GBS 6313 also resulted in a complete loss of fibrinogen binding in the respective mutant, indicating that FbsA is the major fibrinogen-binding protein of this strain. As the fbsA gene was detected in nearly every clinical isolate of GBS tested, it can be speculated that FbsA is a general fibrinogen receptor of GBS.
Complement opsonization is generally considered to be important in defending against GBS infections (Wessels et al., 1995) . However, GBS serotype III strains that possess sialic acid as terminal moiety in their capsule polysaccharide are relatively resistant to opsonophagocytosis in vitro in the absence of type-specific antibody (Edwards et al., 1980) . In the present study, GBS strains 6313 and 6313DfbsA, both belonging to serotype III, exhibited identical growth rates in media devoid of complement. Both strains also revealed growth in human blood, suggesting a low titre of GBS-specific antibodies in the blood used. However, compared with GBS 6313, growth of GBS strain 6313DfbsA was significantly impaired in whole human blood, indicating a reduced resistance of GBS 6313DfbsA to opsonization. This finding suggests that FbsA interferes with the activation of complement, thus contributing to the resistance of GBS against opsonophagocytosis.
A remarkable feature of FbsA is the presence of an extensive internal repeat region. Naturally occurring tandem repeat sequences are frequently found in streptococci and staphylococci (Fischetti, 1989) . Their evolution is characterized by genetic instability, which may arise from DNA polymerase slippage, unequal cross-over during recombination processes and gene conversions Hollingshead et al., 1987) . As a consequence, the number of repeats of a protein may vary significantly between different strains, and the single elements of a repeat region may be highly similar to each other as they evolved from each other. As we were able to demonstrate, the number of repeats of FbsA varied significantly between different clinical isolates of GBS. Strikingly, all but the last repeat of FbsA from strain SS1169 carry D12, whereas those from the other strains reveal E12. This size variation and the divergence of repeats between individual proteins indicates that the repeat region of FbsA is genetically unstable and prone to intragenic recombination and slipped strand mispairing during DNA replication. Similar mechanisms have also been discussed for the highly repetitive proteins Rib and a from GBS (Wästfelt et al., 1996) . Expansions and contractions of repeat regions are expected to generate divergent repeats at the end of the repeat region, as described for the M6 protein of GAS (Hollingshead et al., 1986) . Interestingly, the last repeat of the individual FbsA proteins always represents a minor variant of the standard repeat sequence. This is especially true for the FbsA protein from strain SS1169, in which only the last repeat carries E12, whereas all the other repeats reveal D12. This again supports the hypothesis of genetic instability of the repeat region of fbsA. However, the repeat region of the single FbsA proteins reveals the presence of two or three different species of repeats that differ from each other by one or two amino acid substitutions. This is in contrast to the repeats of the highly repetitive proteins Rib and a from GBS, which are even identical at the DNA level (Michel et al., 1992; Wästfelt et al., 1996) . It can therefore be suggested that recombination between single repeats of fbsA occurs infrequently in GBS, which is in contrast to the situation for the genes encoding Rib and a.
The characterization of truncated forms of FbsA identified the repeat region of FbsA as mediating fibrinogen binding. Similarly, the GAS proteins M1 and M5 have been shown to interact with fibrinogen via their B-repeat domains (Ringdahl et al., 2000) , and also the Staphylococcus aureus proteins coagulase and Efb are known to bind to fibrinogen by homologous repetitive sequences (McDevitt et al., 1992; Wade et al., 1998) . Ligand binding by repetitive sequences offers the possibility for the interaction of one receptor with several ligand molecules, thus resulting in an unequal stoichiometry. Interestingly, our competition experiments strongly indicate that fibrinogen binding of FbsA is dependent on the number of repeats. However, an increase in the number of repeats in FbsA may either increase the affinity of each repeat for fibrinogen and/or increase the number of binding sites for fibrinogen. Further studies are required to elucidate the biochemical basis for the dependency of fibrinogen binding on the number of repeats in FbsA.
Numerous fibrinogen-binding domains have so far been identified in bacterial proteins from different species (McDevitt et al., 1992; Palma et al., 1998; Meehan et al., 2000; Ringdahl et al., 2000; Vasi et al., 2000; Hartford et al., 2001) . However, the fibrinogen binding sites of many of these fibrinogen receptors have been confined to rather large polypeptides. It is therefore speculated that the fibrinogen binding site of these proteins requires a definite conformation that is only maintained by a rather large polypeptide (Ringdahl et al., 2000) . However, the protein Efb from S. aureus was shown to contain two fibrinogen binding sites, which were localized on two distinct stretches of 20 amino acids . As evidenced by our competition and spot membrane experiments, even a single repeat unit of FbsA is capable of binding to fibrinogen. This repeat unit is therefore the smallest bacterial fibrinogen-binding domain identified so far. Our results also indicate that the repeat region of fbsA does not require a certain conformation to allow fibrinogen binding. However, in our competition experiments, significantly higher amounts of the repeat-derived synthetic peptide had to be used to obtain the same amount of inhibition as with FbsA protein. This indeed suggests conformational differences between an isolated repeatderived peptide and those repeats within a mature protein, as has also been discussed for the fibrinogen-binding proteins M1 and M5 from GAS (Ringdahl et al., 2000) .
The inspection of the repeat region of different FbsA proteins revealed a combination of A11V, E12D and R14K substitutions. Although these substitutions have to be regarded as conservative amino acid exchanges, it was interesting to analyse their effect on binding to fibrinogen. In spot-blot experiments, all these exchanges were shown not to affect the binding of human fibrinogen to the repeat, suggesting that all types of repeat of the different FbsA molecules are indeed functional. In particular, the R14K substitution in the repeat region of FbsA is impressive, as any other amino acid in this position leads to a significant reduction in fibrinogen binding. It can therefore be speculated that the repeat units of FbsA are under high selective pressure to maintain fibrinogen-binding activity.
Experimental procedures
Bacterial strains and culture conditions
GBS strains 6313 (serotype III) and SS1169 (serotype V) represent reference strains and have been described previously (Wibawan and Lämmler, 1992) . GBS strains 706 S2 (serotype Ia) and 176 H4A (serotype II) were kindly provided by G. S. Chhatwal (GBF Braunschweig). GBS strain O90R (ATCC 12386) is a derivative of the serotype Ia strain O90. All GBS strains belonging to the serological groups Ia, Ib, II, III and V are clinical isolates and were isolated from infected neonates, whereas GBS strains from group IV were isolated from cows with mastitis (Chhatwal et al., 1985) . E. coli DH5a (Hanahan, 1985) was used for cloning purposes, and E. coli BL21 (Dubendorff and Studier, 1991) served as host for the production of FbsA fusion proteins.
GBS was cultivated at 37°C in Todd-Hewitt yeast broth (THY) containing 1% yeast extract To determine the growth rate of GBS strain 6313 and 6313DfbsA, 50 ml of prewarmed THY or heat-inactivated human serum was inoculated 1:100 with an overnight culture of the bacteria, and the optical density (OD 600 ) of the culture was measured for 10 h at 30 min intervals. E. coli was grown at 37°C in Luria broth (LB), and clones carrying cosmid pTEX5236 or plasmid pET28a were selected in the presence of chloramphenicol (15 mg ml 
Antibodies, enzymes, peptides and human proteins
Affinity-purified rabbit anti-fibrinogen and peroxidase-labelled anti-rabbit antibodies were obtained from Dako Biochemicals. Peroxidase-labelled goat anti-mouse antibodies were purchased from Dianova. Monoclonal anti-his tag antibodies were obtained from Roche Diagnostics. Purified rabbit antifibronectin antibodies, trypsin, pronase and human fibrinogen were purchased from Sigma-Aldrich. Fibrinogen (Sigma) was passed through a gelatin-Sepharose column to remove residual contaminating fibronectin in the preparation. The purity of the fibrinogen preparation was confirmed by SDS-PAGE and Coomassie staining and by Western blotting using anti-fibronectin antibodies. Synthetic peptides for spot membrane analysis and inhibition experiments were synthesized as described previously (Frank and Overwin, 1996) .
Plasmids and cosmids used for cloning purposes
A cosmid gene library from GBS 6313 (Reinscheid et al., 2001) was used for the isolation of the fbsA gene from GBS. Low-copy cosmid pTEX5236 was also used for subcloning of the fbsA gene after partial digestion of an fbsA-carrying cosmid with Sau3A. Plasmid pET28a (Novagen) was used for the synthesis of the hexahistidyl-tagged FbsA fusion proteins, which were constructed as follows. A truncated fbsA gene, devoid of the coding region of the signal peptide and the membrane-spanning domain, was polymerase chain reaction (PCR) amplified from chromosomal DNA of GBS 6313 using the primers 5¢-GTCCTGTATCTGCCATGGAT AGTGTTGG and 5¢-CCGCGGATCCACATTTTGATCATCAC CTG. The repeat-encoding region of fbsA was amplified with the primers 5¢-GTCCTGTATCTGCCATGGATAGTGTTGG and 5¢-CCGCGGATCCCCTATAAGTTGACCTAC. Amplification of the non-repeat region of fbsA was performed with the primers 5¢-TGCTTTGCCATGGTAGGTCAACTTATAGGG and 5¢-CCGCGGATCCACATTTTGATCATCACCTG. The NcoI and BamHI restriction sites used for cloning are underlined. After digestion of the fbsA-derived PCR products and plasmid pET28a with NcoI and BamHI, the fbsA derivatives were ligated into pET28a and transformed into E. coli BL21. Plasmid pETfbsA-9, carrying fbsA with nine internal repeats, was constructed by partial digestion of pETfbsA-19 with XbaI, subsequent religation and transformation into E. coli BL21.
Southern and Northern blot analysis
Chromosomal DNA from GBS was prepared as described elsewhere (Pospiech and Neumann, 1995) . To analyse the distribution of fbsA among different clinical isolates of GBS, their chromosomal DNA was digested with HindIII and hybridized to a digoxigenin (DIG)-labelled fbsA probe, which was obtained by PCR with the primers 5¢-GTCCTGTATCTGC TATGGATAGTGTTGG and 5¢-ACATTTTGATCATCACCTG. This fbsA-specific probe was also used in Northern hybridizations. For Northern blot analysis, total RNA from GBS 6313 was prepared as described previously (Reinscheid et al., 2001) . Labelling, hybridization, washing and detection in Southern and Northern blots was performed using the DIG labelling and detection kit (Roche Diagnostics) according to the manufacturer's instructions with subsequent detection by chemiluminescence.
PCR amplification and sequencing of fbsA from different GBS strains
The fbsA gene was amplified from the chromosome of the GBS strains 706 S2, 176 H4A, O90R and SS1169 by PCR using the primers 5¢-TTACCGTAGCCTGTATCACC and 5¢-CGACCTACGATAGCAACG, and the PCR products were subsequently sequenced. The fbsA sequences from the GBS strains 706 S2, 176 H4A, O90R and SS1169 were submitted to the EMBL database and assigned the accession numbers AJ437622, AJ437621, AJ437620 and AJ437619 respectively. The nucleotide sequence of the fbsA gene from strain 6313 (accession number AJ421083 in the EMBL database) was obtained by sequencing the 2.6 kb insert of pTEXfbsA. GBS strains that had shown more than one fbsA-specific band in Southern blot analysis were tested further by PCR with the fbsA-specific primers 5¢-TGGATAGTGTTGGAAATC and 5¢-ACATTTTGATCATCACCTG.
Construction of an fbsA deletion mutant
The thermosensitive plasmid pG + host6 (Appligene) was used for targeted deletion of the fbsA gene in GBS 6313. Two fragments flanking the fbsA gene were amplified by PCR using the primer pairs fbsA_del1 (5¢-CCGCGGATCC GAATATGCTACCATCAC) and fbsA_del2 (5¢-CCCATCCA CTAAACTTAAACATTCCTGATTTCCAAGTTC) as well as fbsA_del3 5¢-TGTTTAAGTTTAGTGGATGGGGCTGCGGTT TGAGACGC and fbsA_del4 5¢-TGGCACAAGCTTTACCTG CTGAGCGACTTG. Complementary DNA sequences in the primers fbsA_del2 and fbsA_del3 are shown in italics, and the BamHI and HindIII restriction sites in primers fbsA_del1 and fbsA_del4 are underlined. The fbsA-flanking PCR products were mixed with each other in equal amounts and subjected to cross-over PCR using primers fbsA_del1 and fbsA_del4. The resulting PCR product consisted of the fbsAflanking regions on a single DNA fragment. The cross-over PCR product and plasmid pG + host6 were digested with BamHI and HindIII, ligated and transformed into E. coli DH5a. The resulting plasmid, pG + DfbsA, was transformed into GBS 6313, and transformants were selected by growth on erythromycin agar at 30°C. Cells in which pG + DfbsA had integrated into the chromosome were selected by growth of the transformants at 39°C with erythromycin selection as described previously (Maguin et al., 1996) . Four of such integrant strains were serially passaged for 3 days in liquid medium at 30°C without erythromycin selection to facilitate the excision of plasmid pG + DfbsA, leaving the desired fbsA deletion in the chromosome. Dilutions of the serially passaged cultures were plated onto agar, and single colonies were tested for erythromycin sensitivity to identify pG + DfbsA excisants. Chromosomal DNA from GBS 6313 and 24 erythromycin-sensitive GBS excisants was tested by Southern blot after HindIII digestion using a DIG-labelled fbsA flanking fragment obtained with the primers fbsA_del3 and fbsA_del4.
General DNA techniques
Conventional techniques for DNA manipulation, such as restriction enzyme digests, PCR, ligation, transformation by electroporation and Southern blotting, were performed as described by Sambrook et al. (1989) .
Binding of soluble 125 I-labelled fibrinogen to GBS
Purified human fibrinogen was radiolabelled with 125 I using the chloramin T method (Hunter and Greenwood, 1962) . Binding of labelled fibrinogen to GBS was performed essentially as described by Chhatwal et al. (1985) . Briefly, overnight cultures of GBS were pelleted by centrifugation, washed twice with phosphate-buffered saline (PBS) supplemented with 0.02% Tween 20 (PBST) and adjusted photometrically to a transmission of 10% at 600 nm. A total of 0.2 ml of the bacterial suspension was added to 20 ml of 125 I-labelled fibrinogen containing 23 ng of fibrinogen. After incubation for 1 h at room temperature, the streptococci were sedimented by centrifugation and washed with 1 ml of PBST. The radioactivity of the pellet was finally measured in a gamma counter (Packard Instruments). The amount of bacterial-bound fibrinogen was calculated as the percentage of total radiolabelled fibrinogen added to the bacteria. For determination of the fibrinogen dissociation constant, binding of radiolabelled fibrinogen to GBS was measured in the presence of different amounts of unlabelled fibrinogen. Briefly, 20 ml of Fibrinogen (nM) = (mg of fibrinogen in the test ¥ 1.0/0.32 ml ¥ 1000 ml l -1 )/330 mg nmol -1 .
Accordingly, the concentration of radiolabelled fibrinogen (23 ng/0.32 ml) was calculated to be 0.22 nM, and the amount of unlabelled fibrinogen in the assays ranged between 0.303 nM and 189 nM. The total concentration of fibrinogen in the test was calculated as the sum of the concentrations of labelled and unlabelled fibrinogen in the experiment. To determine the total concentration of fibrinogen bound to GBS, the percentage of GBS-bound radiolabelled fibrinogen was multiplied by the total concentration of fibrinogen in the test. The concentration of free fibrinogen was determined by subtracting the concentration of bound fibrinogen from the total concentration of fibrinogen. For the determination of the fibrinogen dissociation constant, the data were subsequently plotted according to Scatchard. In inhibition experiments, the binding of 23 ng of radiolabelled fibrinogen to 0.2 ml of GBS (T = 10%) was determined in the presence of various amounts of FbsA fusion proteins, Bsp fusion protein or synthetic peptides. Each experiment was repeated at least three times in triplicate.
Binding of FITC-labelled GBS to immobilized fibrinogen
Terasaki plates were coated with human fibrinogen, and the binding of FITC-labelled bacteria to the immobilized fibrinogen was measured as described by Podbielski et al. (1999) .
Preparation of FbsA and Bsp fusion proteins
FbsA and Bsp (Reinscheid et al., 2002) fusion proteins were synthesized in recombinant E. coli BL21 by the addition of 1 mM IPTG after the culture had reached an optical density of 1.0. The cells were disrupted using a French Press cell, and purification of the fusion protein was performed according to Qiagen's instructions using Ni 2+ affinity chromatography.
However, the amount of FbsA-C obtained was not sufficient to use FbsA-C as a control in testing the inhibition of fibrinogen binding to GBS in the presence of different proteins.
Screening for fibrinogen-binding colonies
Cosmid-carrying E. coli clones were transferred in duplicate to tetracycline-containing LB plates and incubated overnight. The next day, the colonies from one plate were transferred to nitrocellulose for 6 h. The cells on the filter were lysed by chloroform vapour for 20 min and subsequently incubated overnight in PBS with 1 mg ml -1 lysozyme and 1 mM phenylmethylsulphonyl fluoride (PMSF). The membrane was blocked overnight with 10% skim milk in PBS and subsequently probed for binding of human fibrinogen as described below.
Western blot and spot membrane analysis
In Western blot experiments, proteins were separated by SDS-PAGE and electroblotted onto nitrocellulose. The membrane was subsequently blocked overnight with 10% skim milk in PBS. For spot membrane experiments, peptides of 16 amino acids were synthesized, and equal amounts of the peptides were spotted directly onto cellulose paper as described previously (Frank and Overwin, 1996) . Blocking was performed in membrane blocking solution (MBS) consisting of 20 ml of casein-based blocking buffer (Genosys Biotechnologies), 80 ml of Tris-buffered saline (TBS), 0.05% Tween 20 and 5 g of sucrose. Probing for fibrinogen binding was performed as described below.
Detection of fibrinogen binding by Western blot, spot membrane and colony blot
Membranes that had been blocked overnight were incubated for 1 h with 2 mg ml -1 human fibrinogen. For Western and colony blot experiments, fibrinogen and antibodies were diluted in PBS, whereas for spot membrane analysis, they were diluted in MBS. After three washes with PBS, the membrane was incubated with anti-fibrinogen antibodies (1:1000 in PBS or MBS) for 1 h. This incubation was followed by three washes with PBS containing 0.05% Tween 20 (PBST) and two washes with PBS. Subsequently, the membrane was incubated for 1 h with peroxidase-labelled anti-rabbit IgG (1:1000 in PBS or MBS). After three washes with PBST and two washes with PBS, bound fibrinogen was detected by chemiluminescence using the ECL kit (Amersham Pharmacia). In control experiments, no cross-reactivity of the used antibodies with the immobilized proteins and peptides was detected.
Opsonophagocytosis assay
Resistance to phagocytosis was measured as described by Podbielski et al. (1996) . Briefly, a growing culture of GBS was adjusted to 10 3 colony-forming units (cfu) ml -1
. A sample of 100 ml of the suspension was added to 300 ml of heparinized human blood, and the reaction mixture was incubated at 37°C with end-over-end rotation for 3 h. Pre-and postincubation aliquots were serially diluted and plated onto THY agar for overnight culture. For each strain, the ratio of cfu before and after 3 h incubation with human blood was calculated. Each experiment was performed three times in triplicate.
